Tri Locum Partners
Latest statistics and disclosures from Tri Locum Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ABBV, TEVA, KVUE, REGN, GEHC, and represent 39.82% of Tri Locum Partners's stock portfolio.
- Added to shares of these 10 stocks: KVUE (+$14M), ASND (+$13M), BIIB (+$12M), LEGN (+$6.2M), PRAX (+$5.5M), SRRK, ARGX, ABBV, GEHC, XENE.
- Started 5 new stock positions in ASND, LEGN, BIIB, PRAX, SRRK.
- Reduced shares in these 10 stocks: AMGN (-$29M), DXCM (-$25M), , TEVA (-$8.8M), WST (-$8.4M), NTRA (-$8.3M), Praxis Precision Medicines I (-$8.3M), SILK (-$8.0M), XFOR (-$6.8M), .
- Sold out of its positions in SLRN, ALPN, AMGN, APH, AMLX, ELV, AM, DXCM, EDIT, ETNB.
- Tri Locum Partners was a net seller of stock by $-114M.
- Tri Locum Partners has $219M in assets under management (AUM), dropping by -30.05%.
- Central Index Key (CIK): 0001826434
Tip: Access up to 7 years of quarterly data
Positions held by Tri Locum Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Tri Locum Partners
Tri Locum Partners holds 24 positions in its portfolio as reported in the December 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Abbvie (ABBV) | 11.9 | $26M | +16% | 168k | 154.97 |
|
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 8.6 | $19M | -31% | 1.8M | 10.44 |
|
| Kenvue Put Option (KVUE) | 6.9 | $15M | +1170% | 699k | 21.53 |
|
| Regeneron Pharmaceuticals (REGN) | 6.4 | $14M | -19% | 16k | 878.29 |
|
| Ge Healthcare Technologies I Common Stock (GEHC) | 6.1 | $13M | +30% | 172k | 77.32 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 5.7 | $13M | NEW | 100k | 125.95 |
|
| Avadel Pharmaceuticals Sponsored Adr (AVDL) | 5.4 | $12M | -14% | 840k | 14.12 |
|
| Biogen Idec (BIIB) | 5.4 | $12M | NEW | 46k | 258.77 |
|
| Catalent (CTLT) | 5.4 | $12M | -8% | 262k | 44.93 |
|
| Axsome Therapeutics (AXSM) | 4.8 | $10M | -8% | 131k | 79.59 |
|
| Xenon Pharmaceuticals (XENE) | 4.7 | $10M | +31% | 226k | 46.06 |
|
| Argenx Se Sponsored Adr (ARGX) | 4.2 | $9.2M | +68% | 24k | 380.43 |
|
| Natera (NTRA) | 4.1 | $8.9M | -48% | 142k | 62.64 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 2.8 | $6.2M | NEW | 102k | 60.17 |
|
| Madrigal Pharmaceuticals (MDGL) | 2.7 | $5.9M | -24% | 26k | 231.38 |
|
| Verona Pharma Sponsored Ads (VRNA) | 2.7 | $5.8M | -7% | 293k | 19.88 |
|
| Praxis Precision Medicines I Com New (PRAX) | 2.5 | $5.5M | NEW | 249k | 22.28 |
|
| Astria Therapeutics (ATXS) | 1.9 | $4.2M | -9% | 543k | 7.68 |
|
| Astrazeneca Sponsored Adr (AZN) | 1.8 | $4.0M | +32% | 59k | 67.35 |
|
| Scholar Rock Hldg Corp (SRRK) | 1.8 | $3.9M | NEW | 207k | 18.80 |
|
| Arcturus Therapeutics Hldg I (ARCT) | 1.6 | $3.5M | -47% | 111k | 31.53 |
|
| Immatics SHS (IMTX) | 1.3 | $2.9M | -9% | 276k | 10.53 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 1.3 | $2.9M | -10% | 48k | 60.39 |
|
| Femasys (FEMY) | 0.0 | $35k | -52% | 36k | 0.97 |
|
Past Filings by Tri Locum Partners
SEC 13F filings are viewable for Tri Locum Partners going back to 2020
- Tri Locum Partners 2023 Q4 filed Feb. 14, 2024
- Tri Locum Partners 2023 Q3 filed Nov. 14, 2023
- Tri Locum Partners 2023 Q2 filed Aug. 14, 2023
- Tri Locum Partners 2023 Q1 filed May 15, 2023
- Tri Locum Partners 2022 Q4 filed Feb. 14, 2023
- Tri Locum Partners 2022 Q3 filed Nov. 14, 2022
- Tri Locum Partners 2022 Q2 filed Aug. 15, 2022
- Tri Locum Partners 2022 Q1 filed May 16, 2022
- Tri Locum Partners 2021 Q4 filed Feb. 14, 2022
- Tri Locum Partners 2021 Q3 filed Nov. 15, 2021
- Tri Locum Partners 2021 Q2 filed Aug. 16, 2021
- Tri Locum Partners 2021 Q1 filed May 17, 2021
- Tri Locum Partners 2020 Q4 filed Feb. 16, 2021